FDA approves first drug for rare genetic brain disorder
The U.S. Food and Drug Administration has approved Infilbray (venglustat), the first drug to treat neurological symptoms of type 3 Gaucher disease, according to FOX 5 Atlanta. The drug is approved for patients weighing at least 15 kilograms, or about 33 pounds.
Type 3 Gaucher disease is a rare inherited condition where the body cannot break down fatty substances properly because of a faulty enzyme. These substances build up in organs, tissues, and the brain, causing serious health problems over time. Unlike type 1 Gaucher disease, type 3 affects the brain and nervous system, leading to difficulties with balance, coordination, speech, memory, and thinking that can worsen over time.
Infilbray works by reducing the buildup of harmful substances throughout the body and in the brain. According to the FDA, the drug's ability to reach the brain means it can address the root cause of neurological symptoms. The Acting FDA Commissioner said the approval brings an important new treatment option to patients and their healthcare providers.
Sources
- FOX 5 Atlanta: US approves first drug for rare genetic neurological disorder
- FOX 5 DC: US approves first drug for rare genetic neurological disorder
- FOX 13 Tampa Bay: US approves first drug for rare genetic neurological disorder